Abattis Bioceuticals Corp Stock Fundamentals
ATTBF Stock | USD 0.0001 0.00 0.00% |
Abattis Bioceuticals Corp fundamentals help investors to digest information that contributes to Abattis Bioceuticals' financial success or failures. It also enables traders to predict the movement of Abattis Pink Sheet. The fundamental analysis module provides a way to measure Abattis Bioceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Abattis Bioceuticals pink sheet.
Abattis |
Abattis Bioceuticals Corp Company Shares Outstanding Analysis
Abattis Bioceuticals' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Abattis Bioceuticals Shares Outstanding | 477.8 M |
Most of Abattis Bioceuticals' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Abattis Bioceuticals Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition |
Based on the latest financial disclosure, Abattis Bioceuticals Corp has 477.8 M of shares currently outstending. This is 164.66% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The shares outstanding for all United States stocks is 16.44% higher than that of the company.
Abattis Bioceuticals Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Abattis Bioceuticals's current stock value. Our valuation model uses many indicators to compare Abattis Bioceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Abattis Bioceuticals competition to find correlations between indicators driving Abattis Bioceuticals's intrinsic value. More Info.Abattis Bioceuticals Corp is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Abattis Bioceuticals' earnings, one of the primary drivers of an investment's value.Abattis Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Abattis Bioceuticals' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Abattis Bioceuticals could also be used in its relative valuation, which is a method of valuing Abattis Bioceuticals by comparing valuation metrics of similar companies.Abattis Bioceuticals is currently under evaluation in shares outstanding category among its peers.
Abattis Fundamentals
Return On Equity | -0.28 | |||
Return On Asset | -0.16 | |||
Operating Margin | (10.96) % | |||
Current Valuation | 4.08 M | |||
Shares Outstanding | 477.8 M | |||
Shares Owned By Institutions | 0.02 % | |||
Price To Earning | (5.83) X | |||
Price To Book | 0.38 X | |||
Price To Sales | 1.33 X | |||
Revenue | 356.88 K | |||
Gross Profit | 241.34 K | |||
EBITDA | (2.9 M) | |||
Net Income | (3.04 M) | |||
Cash And Equivalents | 2.4 M | |||
Total Debt | 150.86 K | |||
Debt To Equity | 0.01 % | |||
Current Ratio | 0.73 X | |||
Book Value Per Share | 0.02 X | |||
Cash Flow From Operations | 9.41 M | |||
Earnings Per Share | (0.01) X | |||
Number Of Employees | 32 | |||
Beta | -60.6 | |||
Market Capitalization | 473.03 K | |||
Total Asset | 19.26 M | |||
Retained Earnings | (10.13 M) | |||
Working Capital | (588 K) | |||
Current Asset | 260 K | |||
Current Liabilities | 848 K | |||
Z Score | 1.8 | |||
Net Asset | 19.26 M |
About Abattis Bioceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Abattis Bioceuticals Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Abattis Bioceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Abattis Bioceuticals Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada. ABATTIS BIOCEUTICALS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in Abattis Pink Sheet
Abattis Bioceuticals financial ratios help investors to determine whether Abattis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Abattis with respect to the benefits of owning Abattis Bioceuticals security.